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1. Introduction
The prognosis of patients infected with human immunodeficiency virus (HIV) type 1 has
dramatically improved since the advent of the highly active antiretroviral therapy
(HAART), which have enabled sustained suppression of HIV replication and recovery of
CD4+ T cells count [1-3]. However, many patients in resource-poor settings still start
HAART at a late stage of HIV infection when they already have advanced immunodeficien‐
cy [4,5]. Immune reconstitution in HIV infected patients is characterized by replenishment
of immune cells depleted directly or indirectly by HIV infection, by regeneration of primary
and secondary lymphoid organs, by restoration of pathogen-specific T, B and NK cells and
by a regulation of the reconstituted immune system [2]. It is unclear whether complete im‐
mune reconstitution ever occurs but individuals with human immunodeficiency virus infec‐
tion starting antiretroviral therapy when they are very immunodeficient are susceptible to
immune reconstitution disorders. This phenomenon is known as a multitude of names in‐
cluding “immune reconstitution inflammatory syndrome (IRIS)”, “immune reconstitution or
restoration disease” (IRD) or immune reconstitution syndrome” and includes various forms
of a clinical deterioration as a consequence of a rapid and dysregulated restoration of anti‐
gen specific immune responses causing an exuberant inflammatory reaction and a cytokines
storm [1-3]. This was first noted following the introduction of zidovudine monotherapy in
the early 1990s, when localized forms of Mycobacterium avium intracellulare (MAI) infection
where observed in association with the recovery rather than failure of cellular immune re‐
sponse [6]. Later, in 1992, French MA et al showed that the disease associated with Mycobac‐
terium avium complex (MAC) infection occurred after nucleoside analogue therapy and
correlated with restoration of delayed hypersensitivity (DTH) responses to mycobacterial
antigens [7].
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2. Definition and epidemiology
IRIS is a well established entity still lacking of a consistent definition due to a wide variety
of pathogens and disease processes involved. It has been associated with herpetic, mycobac‐
terial and cryptococcal infections, Kaposi’s sarcoma, non – Hodgkin lymphoma and pro‐
gressive multifocal leukoencephalopathy. Non AIDS defining pathologies such as
sarcoidosis, Graves disease and rheumatic disease can also occur [1-3]. General case defini‐
tions have been proposed by Shelburne et al (2009), French MA et al (2004) and by Robertson J
et al (2006) [8,9,10] but diagnostic criteria for IRIS have not been standardized except for TB-
IRIS [3, 11]. This syndrome can be elicited by infectious and non infectious antigens and
may arise in two different settings, depending on whether HAART was started in a patient
treated for an ongoing opportunistic infection or in a clinically stable patient with or without
requiring primary prophylaxis [2]. “Unsmasking IRIS” is an immune response against an in‐
fection that was subclinical before the initiation of HAART whereas “paradoxical IRIS” indi‐
cates a condition in which the opportunistic infection is present and treated at the time of
initiation of HAART and worsens on therapy. Unmasking IRIS usually presents within the
first three months of therapy and viable pathogens may be isolated from samples obtained
from affected body sites, particularly when there is tissue necrosis. Paradoxical IRIS is com‐
mon during the first three months of HAART but may present later and frequently immune
response is against non viable pathogens. It occurs in 8-43% of patients with treated tubercu‐
losis and in 4-66% of patients with treated cryptococcal infection becoming an important
concern in poor resources countries [1-3]. Paradoxical IRIS is also exemplified by immune
recovery, which occurs in eyes previously affected by cytomegalovirus (CMV) retinitis. Par‐
ticularly in paradoxical IRIS, clinicians need to exclude alternative explanations for deterio‐
ration, such as failure to treat the opportunistic infection or failure of HAART because of
poor adherence or drug resistance [3].
Some authors suggested using terms of “simultaneous IRIS” for patients who develop IRIS
and a newly diagnosed opportunistic infection (OI) at the same time and “delayed IRIS” for
those with an OI in which IRIS manifests sometimes thereafter [12].
However, although several case definitions for IRIS have been proposed, certain minimum
criteria should be fulfilled in order to diagnose it. First of all, there must be the temporal as‐
sociation between initiation of HAART and subsequent development of symptoms of an in‐
flammatory localized or systemic process, characterized by worsening of clinical or
laboratory parameters despite “favorable” evolution of the HIV surrogate markers [1,2]. A
rise in blood CD4 + T cells is commonly seen in IRIS but it is not an essential element for the
diagnosis and is only a supportive criterion in both of the general case definitions for IRIS
[9,10]. Philips P et al found that about 10% of patients with Mycobacterium avium complex
immune restoration disease haven’t an increased CD4+ T cells count [13]. Neverthless, a lack
of rise in blood CD4 + T cells doesn’t indicate that there has been no restoration of functional
T lymphocyte response. On the other hand, IRIS has been described at higher CD4 + T cells
count, suggesting that functional status of cells has a role in the pathogenesis of IRIS too.
Therefore a falling plasma viral load is a more important indicator than CD4 T cells count
recovery [14].
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The immune restoration outcomes range from minimal morbidity to fatal progression [15].
The immune restoration shows a biphasic pattern and is demonstrated by a decrease in plas‐
ma HIV RNA levels by more than 1 log10 copies/ml and an increase in CD4 + T cells count
from baseline [1,2,16]. Initial recovery of the immune system consists in an increase in mem‐
ory T cells followed by an increase in thymic production of naïve T cells [1,2,16-20]. In addi‐
tion there is the recovery of reduced or damaged secondary lymphoid organs such as the
gut and the mesentheric associated lymphoid tissue, which are often lost due to chronic
HIV- mediated inflammation [21]. The initial and rapid rise of CD4 + T memory cells re‐
leased from compartments into circulation can be detrimental and a mild OI can appear as
an overwhelming infection because memory T cells respond to their antigens more readily
than naïve T cells [2,22].
CD8 + T cells also increase during the first two months of HAART and then tend to return to
baseline [18].
Differentiation between an opportunistic infection with normal presentation and a disorder
with a presentation compatible with unmasking IRIS is particularly difficult and the differ‐
ences between intended HAART – associated immune reconstitution and undesired mani‐
festations of IRIS is probably a continuum [3].The damage may indicate a failure of the
immune system to properly regulate the potency of the immune response [23].
The differential diagnosis includes failure of the antimicrobial therapy in patient with active
infection, manifestations of a new opportunistic infection, unmasking of an ongoing, previ‐
ously undiagnosed infection or manifestation of a diagnosed, ongoing infection in a previ‐
ously unrecognized site of involvement [1-3,16]. Drug toxicity must be ruled out. For
example, hepatitis flares in patients coinfected with hepatitis B virus or hepatitis C virus
may be the result of IRIS in the liver or of HAART- associated hepatotoxicity [2, 24].In occur‐
ring IRIS, inflammation is atypical in presentation or more exaggerated than in immunodefi‐
ciency disease being characterized by pain, suppuration and necrosis and examination of
affected tissue or body fluids samples reveals evidence of an immune response with scarcity
of pathogens, infiltrating lymphocytes and granulomatous reaction [1-3].
IRIS may be estimated to occur in 10% to 50 % of patients starting HAART with similar per‐
centages occurring in children and the incidence varies with the AIDS-defining illness [1-3].
Differences reported in the incidence of IRIS between opportunistic infections seem to be re‐
lated to CD4+ T cells count at baseline [3]. IRIS is common in patients starting HAART with
a low CD4 + T cells count and a CMV retinitis or cryptococcal meningitis whereas Kaposi’s
sarcoma and TB-IRIS have also been described at an high count of CD4 + T cells count [3,25].
Moreover, the variation reported in frequency is due to differences in case definitions and,
above all, to differences in study populations with heterogeneous risk profiles and underly‐
ing burden of opportunistic infections [1,2]. In a recent meta-analysis and systematic review
including 54 cohort studies and 13.103 patients starting HAART of whom 1699 develope
IRIS, the lowest to highest incidence of IRIS by previously diagnosed opportunistic illness
resulted 6,4% in patients with Kaposi’s sarcoma (based on two studies), 12,2% in patients
with Herpes Zoster (based on one study), 15,7% in patients with tuberculosis (based on 16
studies), 16,7% in patients with progressive multifocal leukoencephalopathy (based on two
studies), 19,5% in patients with cryptococcal meningitis (based on six studies) and 37,7% in
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patients with cytomegalovirus retinitis (based on ten studies). In the same review IRIS de‐
veloped in 16,1% of unselected patients starting HAART and the incidence of IRIS associat‐
ed with tuberculosis and cryptococcal meningitis seemed to be lower in cohorts from low
and middle income countries probably due to limited diagnostic capacity in these settings.
The strength of this affirmation is supported by the evidence of an high incidence of IRIS
associated uveitis in all settings: inflammatory reactions, even if moderate, are more likely to
be recognized in the eye than in other organs [3].
Risk factors for IRIS are difficult to establish because of the cohorts differ with regards to the
study populations and the type of IRIS examined. Anyway, several risk factors for IRIS has
been identified and, first of all, the presence of an opportunistic infection at the time of ini‐
tiation of HAART, specially for TB and cryptococcal diseases [1,2]. Müller M et colleagues re‐
ported an analysis stratified by median CD4+ T cells count at the beginning of HAART
showing the different incidence of IRIS [Tab. 1, 3]. Male sex and younger age have been
identified as significant predictors too [15,26].
Initiation of HAART soon after treatment for an opportunistic infection is considered a risk
factor too [1-3,15].
A shorter interval between the treatment of an opportunistic infection and the initiation of
HAART is associated with a higher risk of IRIS in these patients [1-3,15].
3. Pathogenesis
The immunopathological process is still poorly understood but is strictly related with the
provoking pathogen and with host. In fact, some people develop IRIS and others, with simi‐
lar clinical status and risk factors, do not. It remains unclear if the disease mechanisms asso‐
ciated with IRIS are the same for each OI or if there are microbial-driven specific immune
responses that result in different pathologies for each pathogen [12]. Several studies using a
simian immunodeficiency virus model indicate differential expression of viral peptides by
distinct MHC alleles, which could influence the aggressiveness of the immune response di‐
rected toward SIV [27].
Essentially any pathogen that can cause an opportunistic infection in patients with impaired
cellular immune responses can provoke IRIS. It also appears that HIV infection itself can
cause IRIS [28]. Two patients were reported with HIV encephalitis after effective HAART.
Neuropathological features consisted in massive CD8+/CD4- lymphocytes brain infiltration
and in a diffuse microglial hyperplasia [28].
The antigenic stimulus in infectious conditions are either intact viable organism or dead or‐
ganism and their residual antigens whereas autoimmunity to innate antigens are involved
in the non-infectious causes of the syndrome [1-3].
If the pathogen is viral, i.e. CMV or JC, CD8 + - T lymphocytes predominate in inflammatory
cells infiltrates whereas if the pathogen is tuberculous or non tuberculous mycobacteria, a
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protozoan as Leishmania species or a fungus as Cryptococcus neoformans granulomatous
CD4 + - T helper cells type 1 inflammation predominates [1-3].
Price P et al suggested a genetic predisposition and certain genes have been associated with
an increased susceptibility to development of IRIS in presence of mycobacteria and herpes‐
viruses. The TNF α-308*2 carried in linkage disequilibrium with HLA-A2,-B44,-DR4 and
without BAT1 (intron 10)*2 is more common in patients with herpesvirus-associated IRIS
and is not present in any patients who has experienced mycobacterial IRIS. Therefore TNF α
polymorphisms should be considered in the context of the adjacent MHC alleles. The ab‐
sence of C allele of IL6-174 together with TNF α - 308*1 confers an increased relative risk for
mycobacterial IRIS probably due to a limited TNF-mediated bactericidal activity and to a
lower TNFα production in monocytes [29]. The CMV retinitis IRD patients have over 4 years
on HAART progressively increased plasma levels of bioavailable IL-6 and of soluble CD30,
a type 2 (T2) immune response marker and 92% of them result homozygous for
IL12B-3’UTR* 1 suggesting a dysregulation of the T1/T2 balance [30,31]. Th1 cells are charac‐
terized by the production of interferon γ and elicit proinflammatory responses. Th2 cells
produce antiinflammatory and immunosuppressive cytokines (i.e. interleukin 10). [31,32 ].
These considerations suggest that IRIS could be sustained form several immunopathological
mechanisms and that further studies need to better establish the role of cytokines in the dif‐
ferent forms of IRIS [31].
In addition to the reconstitution of immune cell numbers and function, redistribution of
lymphocytes, defects in regulatory function, changes in Th cell profile are also involved [23].
Mycobacterial IRIS usually presents with suppuration of lympho nodes or other organ af‐
fected because of an activation of Th 17 lymphocytes inducing inflammation mediated by
neutrophils [33]. Production of cytokines inducing cellular proliferation is the main mecha‐
nism of IRIS-Kaposi [34]. An unbalanced immune reconstitution of effector and regulatory T
cells in patients receiving HAART has been noted. In particular, two types of T cells seem to
take part to the development of the disease: the proinflammatory Th 17 lymphocytse and
the T regulatory cells. The latter are implied in preventing collateral damage from exuberant
inflammatory responses and may be defective in number and function during IRIS
[1,2,23,31]. A role has been hypotized for NK cells by killer immunoglobulin-like receptors
activity. Macrophages are inappropriately activated in IRIS-TB [1].
Actually serological markers for IRIS diagnosis are lacking. Inflammatory markers, cyto‐
kines and chemokines are shown to be elevated in IRIS, specially IL 6. Paradoxical TB-IRIS
has been associated with elevation of interleukin(IL) -4, IL -6, IL-7, IFN (interferon) γ and
tumor necrosis factor alpha (TNF-α) and cryptococcal meningitis with increased pre-
HAART levels of C reactive protein (CRP), IL-4 e IL-17 and lower levels of vascular endo‐
thelial growth factor (VEGF), granulocytes colony-stimulating factor (G-CSF) and TNF-α
during clinical events [1,31,35].
To sum up, IRIS has been associated with certain human leucocyte antigen (HLA) profiles
and regulatory cytokine genes polymorphisms but further research is needed to evaluate
their potential role in identifying patients at risk, developing better therapeutics and moni‐
toring response to therapy.




Lots of clinical manifestation have been described in occurring IRIS.
Several pathogens have been associated with IRIS, including JC virus, herpes viruses, BK vi‐
rus, Parvovirus B19, human T lymphotropic virus type 2, Epstein Barr virus, HHV 8, Cyto‐
megalovirus, Cryptococcus neoformans, Toxoplasma gondii. Mycobacterium tuberculosis,
Mycobacterium leprae and Mycobacterium avium complex (MAC) contribute too [1-3,15].
The antigens driving IRIS often belong to opportunistic pathogens but sometimes IRIS can
be a result of HIV- specific responses [1-3,15].
TB-IRIS manifestations include worsening respiratory symptoms, fever, lymphonode en‐
largement and suppuration, appearance of new infiltrates and mediastinal lymphoadenop‐
athy on chest radiograph, visceral or cutaneous abscesses, pleural and pericardial effusion
and rarely intracranial tubercoloma, acute renal failure, meningitis and cognitive impair‐
ment. Moreover abdominal TB-IRIS can present with non-specific abdominal pain and ob‐
structive jaundice. Differential diagnosis from drug-resistant tuberculosis is difficult
[15,36-39]. MAC remains the most reported atypical mycobacterium and the most common
manifestation in MAC-IRIS is fever with suppurative painful lymphadenitis followed by
pulmonary disease but involvement of joints, spine, skin and soft tissue has also been re‐
ported. In contrast to disseminated MAC disease of advanced AIDS, MAC-IRIS usually
presents as localized disease [40]. Mycobacterial IRIS has to be distinguished from sarcoido‐
sis that can also occur in the context of IRIS [1]. Measurement of a delayed-type hypersensi‐
tivity response to tuberculin by a skin test may help to differentiate immune reconstitution-
associated sarcoidosis from mycobacterial IRIS, because a response is absent in patients with
sarcoidosis but is often present in patients with mycobacterial IRIS [1,2,7, 41,42].
Patients with Pneumocystis jirovecii IRIS manifest recurrence of fever, worsening hypoxia
and fresh pulmonary infiltrates on chest radiograph. In addition to the general risk factors,
PaO2 < 70 mmHg and a recent completion of steroid therapy for Pneumocystis jirovecii
pneumonia promote IRIS [1, 43,44].
CNS-IRIS occurs at much lower frequencies with about 0,9-1,5% of patients developing
some CNS-IRIS after initiating HAART [45-47]. The heightened immune response in a rela‐
tively closed space leads to raised intracranial pressure, with potentially irreversible dam‐
age. Diagnosis of CNS-IRIS is difficult because CNS is a region of limited access and
requires pathological confirmation and invasive procedures. A worsening of clinical neuro‐
logical status can be accompanied by new neuroradiological findings or by deterioration of
previous findings with T cell infiltrates into the CNS. Depending on the severity of CNS-
IRIS it may be classified as asymptomatic, symptomatic and catastrophic. Asymptomatic
CNS-IRIS consists in radiological changes only, such as increased enhancement. Sympto‐
matic CNS-IRIS is characterized by clinical deterioration in neurological function with new
changes on MRI scan of brain. In the catastrophic CNS-IRIS severe neurological deficits oc‐
cur such as coma and imminent signs of cerebral herniation [12, 45-48]. JC virus is the causa‐
tive agent of PML and one of the most devastating of the OIs associated with IRIS leading to
a 42% mortality. Of the approximate 5% of HIV + patients who develop PML up to 19% are
PML-IRIS patients. Differential diagnosis between PML and PML-IRIS can be done by MRI:
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the presence of contrast enhancement suggest an inflammatory response and is indicative of
PML-IRIS. The response to steroids confirms the diagnosis. The prognosis of delayed PML-
IRIS is worse than the form that begins simultaneously [49,50].
A stroke occurring after initiation of HAART can be due to a vasculitis in the context of a
VZV-IRIS [51]. Genital ulceration related to Herpes Simplex virus and genital warts related
to human papillomavirus are frequently observed [1]. Most commonly CMV is associated
with CMV-IRIS retinitis, vitreitis and uveitis with loss of visual acuity and floaters [1, 52].
CMV ventriculitis without retinal damage has been described [53].
Cryptococcus neoformans is frequently involved in IRIS development. It can provoke a CNS
associated IRIS and a non-CNS IRIS: the first results in an aseptic recurrence of meningitis or
rarely in a cryptococcoma; the second is more common and is a lymphoadenitis or a media‐
stinitis or rarely a cavitary pneumonia. In a patient with cryptococcal meningitis rapidly
worsening because of headache, nausea and vomiting after HAART initiation IRIS has to be
considered above all in presence of sterile inflammation of the CSF, residual cryptococcal
antigens and absence of viable yeast on culture. Patients with Cryptococcus neoformans as‐
sociated IRIS has usually higher opening pressure, white cell count and glucose levels than
patients with Cryptococcus neoformans infection only. Neuroimaging is usually not useful
in cryptococcal meningitis diagnosis but in occurring IRIS evidence of meningeal or choroid
plexus enhancement or linear perivascular enhancement in the sulci at CT scan is frequent
and represent a sign of inflammation [54-57]. Patients with cryptococcal meningitis particu‐
larly with IRIS are likely to develop a communicating idrocephalus due to blockage of CSF
absorption at the arachnoid villi by cryptococcal antigens and by the inflammatory cells.
This is a serious condition that may require drainage by repeated lumbar punctures [48].
There is only a case report of immune reconstitution syndrome occurring in a patient with
Candida meningitis in the literature and a case report of visual loss and detection of EBV in
CSF by PCR after initiation of HAART [12, 58]. In few cases Toxoplasma gondi is the re‐
sponsible agent of CNS-IRIS [59].
Some patients may develop a severe progressive encephalitis after initiation of HAART with
seizures, altered mental status, coma and death. HIV may be detectable in CSF even when
results undetectable in blood. MRI can show diffuse multifocal white matter changes with
associated cerebral edema [12,28].
Given the known associations of Kaposi’s sarcoma with human herpesvirus 8 and non
Hodgkin lymphoma with Epstein Barr virus it is not surprising to observe these cancers oc‐
curring or worsening in the context of IRIS [12,60-63]. Both clinical sudden progression of
established lesions and new Kaposi sarcoma have been described after HAART initiation
[12, 60-62]. HIV-infected patients starting HAART may present manifestations of autoim‐
mune disease like most frequently sarcoidosis and Graves disease but also systemic lupus
erythematosus, rheumatoid arthritis, Reiter’s syndrome, polymyositis and Guillain-Barrè
syndrome [1-3, 64-70]. At last, high levels of CNS inflammation have been demonstrated in
the hippocampus of patients successfully treated with HAART and IRIS could contribute to
pathogenetic mechanism leading to a cognitive impairment [12].
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5. Treatment and prevention
Till now, on the grounds of available data, it appears prudent that HAART should be initiat‐
ed before the onset of severe immunodeficiency. A detailed evaluation should be done for
identification of opportunistic infections before HAART initiation. Patients with high risk
features for the development of IRIS should be identified and OIs should be optimally treat‐
ed if present [1-3, 71-73]. In the context of opportunistic infections, the benefit of reducing
the likelihood of IRIS by deferring HAART must be balanced with the risk of delaying
HAART, above all if patients are severely immunodeficient. The ACTG 5164 is a random‐
ized trial comparing immediate versus deferred antiretroviral therapy initiation in patients
presenting with acute OIs. Significant reduction in clinical progression or death among pa‐
tients who received antiretroviral therapy within 14 days of presenting with acute OI versus
those who deferred antiretroviral therapy until after OI had been treated was found and the
incidence of immune reconstitution events resulted similar between groups [73].
To date, literature is lacking about the optimal time of HAART initiation following a treat‐
ment of opportunistic infections with exception of tuberculosis/HIV coinfection. Regarding
this concern the most recent WHO and DHHS guidelines recommend the initiation of
HAART between 2 and 8 weeks after starting treatment against tuberculosis for patients
with a CD4 count < 200/µl [71,72].
Actually management of patients with IRIS was founded upon clinical observations and ex‐
pert opinions only. In general non steroidal anti-inflammatory drugs should be reserved for
milder manifestations and steroids for cases with severe inflammation. Interruption of
HAART is rarely necessary but could be considered in life threatening situations or when
pathogens involved are not controllable by specific antimicrobial therapy, as JC virus [15].
Stopping HAART may improve symptoms but there is no guarantee that the condition will
not recur once HAART is resumed [74]. In a randomized controlled trial, Meintjes G et al
reported the utility of prednisolone (1.5 mg/kg per day for two weeks followed by 0.75
mg/kg per day for further two weeks) in the treatment of paradoxical tuberculosis-IRIS with
worsening chest radiograph, enlarging lymph node, serous effusion and cold abscess, CNS
manifestations, tracheal compression due to lymphadenopathy and acute respiratory dis‐
tress syndrome (ARDS). For atypical mycobacterial – IRIS treatment is similar to TB-IRIS.
Surgical excision of profoundly enlarged nodes or debridement of necrotic areas is anecdo‐
tally reported [75,76]. Cryptococcal meningoencephalitis IRIS requires prompt control of
raised intracranial pressure and hydrocephalus by serial lumbar punctures. Corticosteroids
are indicated for cerebral oedema and ARDS in pulmonary cryptococcosis [48,77-78]. The
development of PCP-IRIS after discontinuation of steroid therapy suggest a role for the rein‐
troduction of steroids in these patients [44]. In cases of ocular CMV-IRIS systemic or perioc‐
ular steroid injections have been used bur a clear benefit has not been demonstrated. The
role of corticosteroids in PML-IRIS is not clear and a long term treatment may be necessary
until T memory cells and a more directed immune response against JC virus predominates
[50,79]. Unfortunately increased risk of progression of herpes zoster and Kaposi’s sarcoma
and reactivation of latent infections have also been reported with corticosteroids.
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6. Conclusions
The majority of patients with IRIS have a self-limiting disease course but associated morbid‐
ity places a considerable burden on the health care system. Morbidity and mortality rates
vary according to the pathogen and organ involved. Mortality is usually uncommon with
the exception of the setting of opportunistic infections involving the CNS [1]. Lethality rang‐
es from about 3% in patients with tuberculosis to more than 20% in patients with cryptococ‐
cal meningitis, with an higher early mortality in resource-limited settings due to probable
underdiagnoses [3]. The occurrence of IRIS and its contribution to mortality in a given set‐
ting is affected by the relative importance of different infections, the degree of access to fa‐
cilities for diagnosis of such illnesses and the extent of screening for and treatment of
opportunistic infections before starting HAART [80].Research efforts should be focused on
increasing knowledge about IRIS so that diagnostic tests and prevention and treatment
strategies could be improved.
CD4 < 50 μl CD4 > 50 μl
IRIS-TB 20,7% 17,7%
IRIS-cryptococcal meningitis 28,3% 2%
IRIS- CMV retinitis 37,7% No studies
Table 1. Development of IRIS in analysis stratified by median CD4+ cells count at the start of HAART [3]
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